We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLP:NASDAQSimulations Plus, Inc. Analysis

Data as of 2026-06-30 - not real-time

$18.38

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Simulations Plus (SLP) is currently trading at $18.38, marginally above its DCF‑derived fair value of $18.22, indicating a slight premium. The stock’s 20‑day SMA ($17.21) sits below the market price, while the 50‑day and 200‑day SMAs ($15.82 and $15.84) are well underneath, suggesting a short‑term upward bias. Momentum indicators are supportive: RSI is at 68.5 (near‑overbought), MACD shows a bullish crossover with a positive histogram, and volume is on an increasing trend. The recent definitive agreement to be acquired by Altaris for $18.50 per share adds a 26% premium to the 60‑day VWAP, providing a concrete catalyst for upside.
Fundamentally, the company reports strong operating cash flow ($24.4 M) and a healthy cash pile ($41.8 M) versus modest debt ($0.5 M), but profitability remains weak with a negative net profit margin and ROE of –38.8%. Volatility is elevated (50% 30‑day) and beta (1.26) exceeds the market, flagging higher systematic risk. Ongoing securities‑law investigations and class‑action scrutiny introduce additional uncertainty. Overall, the blend of a cash‑out acquisition premium, bullish technicals, and solid liquidity offsets the earnings volatility and regulatory headwinds.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 9/10

Key Factors

  • Acquisition premium of $18.50 cash per share
  • Bullish technical setup (RSI, MACD, SMA crossovers)
  • Increasing volume supporting price momentum

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Pending regulatory and shareholder approvals for the Altaris deal
  • Potential impact of securities‑law investigations
  • Strong cash position offsetting operating losses

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Uncertainty about post‑acquisition integration and strategic direction
  • Historical earnings volatility and negative ROE
  • Sector exposure to healthcare software regulatory changes

Key Metrics & Analysis

Financial Health

Revenue Growth8.30%
Profit Margin-77.96%
P/E Ratio20.3
ROE-38.84%
ROA3.81%
Debt/Equity0.38
P/B Ratio2.8
Op. Cash Flow$24.4M
Free Cash Flow$17.2M
Industry P/E25.9

Technical Analysis

TrendNeutral
RSI68.5
Support$15.29
Resistance$18.57
MA 20$17.21
MA 50$15.82
MA 200$15.84
MACDBullish
VolumeIncreasing
Fear & Greed Index89.91

Valuation

Fair Value$18.22
Target Price$17.25
Upside/Downside-6.15%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.26
Volatility50.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.